Scientific deep-dive

Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ

Semaglutide produced injection site reactions in 1.4% against 1% on placebo. Tirzepatide runs 6–8% against 2%. If you react on one and not the other, that is not your technique.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·2 citations

These two drugs are not the same on this, and the gap is larger than almost anything else separating them. Semaglutide produced injection site reactions in 1.4% of patients against 1% on placebo, barely a difference.[1] Tirzepatide runs 6% to 8% against 2%, rising with dose.[2] If you are getting lumps and redness on one and did not on the other, that is not your technique.

The two drugs, side by side

Injection site reactions and hypersensitivity, from each label's adverse reactions table.
PlaceboDrug
Semaglutide 2.4 mg — injection site reactions[1]1%1.4%
Tirzepatide — injection site reactions, 5/10/15 mg[2]2%6% / 8% / 8%
Tirzepatide — hypersensitivity reactions[2]3%5% / 5% / 5%

The semaglutide label lists what counts as a reaction: itching, redness, inflammation, hardening of the tissue, and irritation.[1] Those are local, they settle, and at 1.4% against 1% they are close to background.

Tirzepatide’s figures behave differently. They roughly triple from placebo at the lowest dose and then flatten (6%, 8%, 8%), the same plateau pattern its gastrointestinal effects show. Getting through the first dose tends to predict the rest.

The serious reaction is a different thing entirely

A lump at the injection site and an allergic reaction to the drug are not two points on one scale. Conflating them is how people either panic about a bruise or ignore something that matters.

The semaglutide label carries serious hypersensitivity in its warnings: anaphylaxis and angioedema have been reported. If one occurs, the instruction is to stop the drug, treat promptly, and monitor until it resolves. The drug then becomes contraindicated, both for the molecule and for any of the excipients in it.[1]

A prior serious reaction is not a caution to weigh. It is a contraindication.
What to act on immediately. Swelling of the face, lips, tongue or throat; difficulty breathing or swallowing; a widespread rash or hives; faintness. That is anaphylaxis or angioedema, not an injection site reaction, and it is emergency care rather than a call to the prescriber. Tell them afterward too, because it changes whether you can ever take this drug again. What happens after a reaction, including whether another GLP‑1 is an option, is in GLP-1 allergic reactions and anaphylaxis.

What is ordinary

  • A small red mark or mild itch for a day or two. Common with any subcutaneous injection, and on the label for both drugs.
  • A firm lump under the skin (induration, in the label’s language). This is why every label asks for site rotation with each dose. Our rotation calendar tracks it, and where to inject covers technique.
  • A small bruise, which is about the needle and the capillary it happened to meet, not the drug.

None of that needs treating. Rotating sites is the one thing that reliably helps, and the label asks for it precisely because repeatedly injecting the same spot is what produces persistent lumps. Itching or a rash that spreads beyond the injection site, or skin that hurts all over, is a different reaction, covered in GLP-1 skin sensitivity, rash and itching.

If reactions are why you want to switch

That is a legitimate reason, and the numbers support it in one direction: someone reacting on tirzepatide has a reasonable expectation of fewer local reactions on semaglutide, because 1.4% against 1% is close to nothing. The reverse is not true.

Weigh that against everything else that differs between them: effect size, cost, coverage and the other side effects. Our tirzepatide timeline and semaglutide timeline set out what each does on the scale, and switching itself has a dose-equivalence problem covered by the switch calculator. A sore spot where you inject is also a different thing from aches elsewhere in the body, which the trials counted separately.

Those label figures describe the approved drugs. A compounded vial is a different preparation, and some carry added ingredients: EllieMD sells compounded semaglutide and tirzepatide injections with B12, L-carnitine or glycine, and Nuform Health sells both as vitamin blends. Because the label’s contraindication reaches the excipients as well as the molecule, ask for the full ingredient list of whatever you inject. Independent Wellness names its three partner pharmacies, which gives that question somewhere to go.

If a switch between molecules is on the table, it is simpler when one prescriber can make it. Lemonaid Health prescribes compounded semaglutide and tirzepatide as well as brand Zepbound, Wegovy and Ozempic, and Noom Med offers compounded microdoses of either drug beside brand Wegovy and Zepbound. Factor Health MD lists compounded liraglutide next to semaglutide and tirzepatide, and every patient there has a video visit with a provider. Check the cost side as well: Coby Health and Boston Medical Group price compounded semaglutide by dose, so a dose change moves the bill.

Embody works the other way: a month of its compounded semaglutide injection costs the same at every dose, and it names RedRock Pharmacy among the pharmacies that fill its prescriptions.

Frequently Asked Questions

It depends which one. On semaglutide they are close to background: 1.4% against 1% on placebo. On tirzepatide they run 6% to 8% against 2%, rising with dose. Redness, itching, inflammation, hardening and irritation are what the label counts.
Because the drugs differ here, and by more than almost anything else separating them. It is not your technique. Tirzepatide's rate is several times semaglutide's in each label's own trials.
Not much after the first step. Tirzepatide's figures run 6%, 8%, 8% across 5, 10 and 15 mg, a jump from placebo to the lowest dose followed by a plateau. Tolerating the first dose largely predicts the rest.
The emergency signs are listed in the warning above. They point to an allergic reaction affecting the airway or the whole body, rather than the skin around the injection. That is emergency care, not a call to the prescriber. It also matters afterward, because a serious reaction makes the drug contraindicated rather than merely risky.
Rotating sites with each dose, which every label asks for. Persistent hardening comes from repeatedly injecting the same spot, and no cream addresses that.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information: injection site reactions 1.4% vs 1%, and Hypersensitivity Reactions including anaphylaxis and angioedema (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Eli Lilly and Company. ZEPBOUND (tirzepatide) — US Prescribing Information, Section 6.1 Adverse Reactions, dose-stratified table (SPL effective 2026-04-22) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

GLP-1 Diarrhea: Why It Doesn't Follow the Dose, and What Has Actually Been Tested

Diarrhea affects 19% to 30% of people on the weight-loss doses. Unlike nausea and vomiting, it stayed flat when semaglutide was tripled and was identical in the tirzepatide vs semaglutide trial. No treatment for it has ever been tested.

9 min read

Tirzepatide Week by Week: What the SURMOUNT Trials Recorded

The dose ladder takes months, not weeks. This sets out what SURMOUNT-1, 2 and 4 recorded at each stage on Zepbound and Mounjaro, and the roughly half of the lost weight that came back when people stopped.

7 min read

What Happens When You Stop a GLP-1: What the Withdrawal Trials Measured

Three trials took semaglutide or tirzepatide away from people who had lost weight on it, two of them by random assignment, and measured what came back: the weight, and the cardiometabolic gains with it.

11 min read

Ozempic, Wegovy and Zepbound While Breastfeeding: What the Labels Say

Ozempic's label does not forbid breastfeeding; the semaglutide tablets and Foundayo advise against it, and tirzepatide is the only GLP-1 with a human milk study on its label. Each label's lactation wording, LactMed's summaries and the small milk studies.

11 min read

Joint Pain, Back Pain and Aches on a GLP-1: What the Trials Counted

No FDA label for these drugs lists joint or back pain, and in most trials both were about as common on placebo. The exception is the 7.2 mg Wegovy trial, and the one pain the labels do list is in the skin.

8 min read

Stomach Pain on a GLP-1: What Is Expected and What Is a Warning Sign

Stomach pain on Ozempic, Wegovy, Mounjaro or Zepbound is usually mild and comes with the dose increases. The labels describe the patterns that are not ordinary, and little of the usual advice has been tested.

8 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

7.3

Found

People who want clinician visits billed to commercial insurance, with compounded medication in the plan price

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →